Unleash Immuno Oncolytics, Inc. — Form D
Unleash Immuno Oncolytics, Inc. of ST. LOUIS, MO, a company, filed a Form D exempt-offering notice with the SEC on 2018-02-22. The offering totals $3.0M, of which $3.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-02-22
- Form: D
- Accession: 0001732374-18-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $3.0M
- Amount sold: $3.0M
- Investors: 1
- Date of first sale: 2018-02-16
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-306188
Issuer
- Name: Unleash Immuno Oncolytics, Inc.
- CIK: 0001732374
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 4320 FOREST PARK AVENUE, SUITE 304, ST. LOUIS, MO, 63108
- Phone: 314-730-0050
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| Ricardo Lisandro Bril | Director | St. Louis, MO |
| Bolten Charles | Director | St. Louis, MO |
| Daniel Katzman | Director | St. Louis, MO |
| Ariel Muslera | Director | St. Louis, MO |
| Daniel Katzman | Executive Officer | St. Louis, MO |
More